Volume | 9,553 |
|
|||||
News | - | ||||||
Day High | 0.69 | Low High |
|||||
Day Low | 0.55 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Regen Biopharma Inc (PK) | RGBP | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.55 | 0.55 | 0.69 | 0.66 | 0.57 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
27 | 9,553 | US$ 0.653766 | US$ 6,245 | - | 0.401 - 2.55 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
14:57:43 | 140 | US$ 0.66 | USD |
Regen Biopharma Inc (PK) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.59M | 3.38M | - | 77k | -1.73M | -0.44 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Regen Biopharma (PK) News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RGBP Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.72 | 0.74 | 0.5462 | 0.5927405 | 4,627 | -0.06 | -8.33% |
1 Month | 0.80 | 0.81 | 0.401 | 0.644925 | 11,218 | -0.14 | -17.50% |
3 Months | 0.79 | 1.05 | 0.401 | 0.7631983 | 14,102 | -0.13 | -16.46% |
6 Months | 1.60 | 1.88 | 0.401 | 0.8778152 | 18,963 | -0.94 | -58.75% |
1 Year | 1.50 | 2.55 | 0.401 | 1.14 | 12,970 | -0.84 | -56.00% |
3 Years | 28.50 | 122.25 | 0.401 | 30.33 | 32,603,800 | -27.84 | -97.68% |
5 Years | 1.65 | 122.85 | 0.0015 | 25.12 | 47,375,293 | -0.99 | -60.00% |
Regen Biopharma (PK) Description
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com. |